Abstract Number: 0185 • ACR Convergence 2024
New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities
Background/Purpose: Systemic Lupus Erythematosus (SLE) disproportionally affects minoritized populations. SLE damage, assessed by SLICC/ACR Damage Index (SDI), is higher in Black than in White US…Abstract Number: 0247 • ACR Convergence 2024
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…Abstract Number: 0437 • ACR Convergence 2024
Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…Abstract Number: 0613 • ACR Convergence 2024
Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects women of childbearing period. SLE increases the risk of adverse pregnancy outcome including spontaneous abortion (SA), which causes emotional stress to…Abstract Number: 0631 • ACR Convergence 2024
Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis
Background/Purpose: Proteinuria is a marker of lupus nephritis (LN) activity, damage, and response to therapy. There is still sparse evidence on the renal outcomes associated…Abstract Number: 0650 • ACR Convergence 2024
Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis
Background/Purpose: Current classification criteria of lupus nephritis (LN) emphasize glomerular pathology, however tubular atrophy and interstitial fibrosis (TAIF) are better predictors of poor…Abstract Number: 0668 • ACR Convergence 2024
There Are No Shortcuts: Electronic Health Record-Generated Tool Does Not Reflect Medication Adherence in Patients with SLEin Bronx, NY
Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is associated with poor outcomes in SLE.1 Electronic Health Record (EHR) platforms collect data on patient medication access through dispensing…Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…Abstract Number: 1006 • ACR Convergence 2024
Associations Between Rheumatic Diseases and Mental Health Disorders
Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…Abstract Number: 1253 • ACR Convergence 2024
Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia
Background/Purpose: Patients with SLE often have concomitant FM or symptoms similar to FM, including chronic pain, fatigue, sleep disturbance, and/or depression, potentially distinct from immune-mediated…Abstract Number: 1280 • ACR Convergence 2024
Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue
Background/Purpose: Fatigue and brain fog are early complaints in adolescents with childhood-onset SLE (cSLE), who experience disease onset during a critical period of brain development.…Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…Abstract Number: 1511 • ACR Convergence 2024
Lupus Nephritis and Response to Treatment in Latin America
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…Abstract Number: 1528 • ACR Convergence 2024
Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a range of pulmonary complications, including Pulmonary Arterial Hypertension (PAH), which affects between 0.5% and 17.5% of…Abstract Number: 1548 • ACR Convergence 2024
Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1), thus blocking the biological activity of…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 150
- Next Page »